| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Masashi Mizuguchi, Maki Ohsawa, Hirofumi Kashii, Atsushi Sat. Brain Symptoms of Tuberous Sclerosis Complex: Pathogenesis and Treatment. International journal of molecular sciences. vol 22. issue 13. 2021-07-23. PMID:34206526. |
tuberous sclerosis complex (tsc) is a congenital disorder caused by a defective suppressor of the mtor system, the tsc1/tsc2 complex. |
2021-07-23 |
2023-08-13 |
mouse |
| Ana Dagge, Luísa Andrade Silva, Sofia Jorge, Estela Nogueira, Mónica Rebelo, Luísa Pint. Fetal Tuberous Sclerosis: Sirolimus for the Treatment of Fetal rhabdomyoma. Fetal and pediatric pathology. 2021-07-20. PMID:34281475. |
sirolimus constitutes a safe and effective treatment for cardiac manifestations of tuberous sclerosis complex (tsc) in children but only four cases describing prenatal treatment of rhabdomyomas with mtor inhibitors have been published. |
2021-07-20 |
2023-08-13 |
Not clear |
| Chen Zhu, Quan Zhou, Cong Luo, Ying Che. Dexmedetomidine Protects Against Oxygen-Glucose Deprivation-Induced Injury Through Inducing Astrocytes Autophagy via TSC2/mTOR Pathway. Neuromolecular medicine. vol 22. issue 2. 2021-07-19. PMID:31654225. |
in addition, dex enhanced the expression of tuberous sclerosis complex 2 (tsc2) in primary cultured astrocytes, while reduced the expression of mammalian target of rapamycin (mtor). |
2021-07-19 |
2023-08-13 |
Not clear |
| Longbo Zhang, Tianxiang Huang, Shannon Teaw, Lena H Nguyen, Lawrence S Hsieh, Xuan Gong, Lindsay H Burns, Angélique Borde. Filamin A inhibition reduces seizure activity in a mouse model of focal cortical malformations. Science translational medicine. vol 12. issue 531. 2021-06-23. PMID:32075941. |
epilepsy treatments for patients with mechanistic target of rapamycin (mtor) disorders, such as tuberous sclerosis complex (tsc) or focal cortical dysplasia type ii (fcdii), are urgently needed. |
2021-06-23 |
2023-08-13 |
mouse |
| Camilla Russo, Anna Nastro, Domenico Cicala, Maria De Liso, Eugenio Maria Covelli, Giuseppe Cinall. Neuroimaging in tuberous sclerosis complex. Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery. vol 36. issue 10. 2021-06-21. PMID:32519125. |
tuberous sclerosis complex (tsc) is a rare autosomal dominant disorder affecting multiple systems, due to inactivating mutations of tsc1 or tsc2 mtor pathway genes. |
2021-06-21 |
2023-08-13 |
Not clear |
| Monika Sugalska, Anna Tomik, Sergiusz Jóźwiak, Bożena Werne. Treatment of Cardiac Rhabdomyomas with mTOR Inhibitors in Children with Tuberous Sclerosis Complex-A Systematic Review. International journal of environmental research and public health. vol 18. issue 9. 2021-06-21. PMID:34062963. |
treatment of cardiac rhabdomyomas with mtor inhibitors in children with tuberous sclerosis complex-a systematic review. |
2021-06-21 |
2023-08-13 |
Not clear |
| William Ching-Yuen Chu, Lorraine Lok-Wing Chiang, Dorothy Chi-Ching Chan, Wilfred Hing-Sang Wong, Godfrey Chi-Fung Cha. Prevalence, mortality and healthcare economic burden of tuberous sclerosis in Hong Kong: a population-based retrospective cohort study (1995-2018). Orphanet journal of rare diseases. vol 15. issue 1. 2021-06-18. PMID:32988393. |
we aim to elucidate the disease impact by accounting the prevalence, survival rate, genetics, mtor inhibitor use and direct costs of tuberous sclerosis complex (tsc) in our local setting. |
2021-06-18 |
2023-08-13 |
Not clear |
| Xiaojun Xiao, Yayuan Zhang, Yujuan Zhang, Lijuan Wang, Hui Lu. Study on the Treatment of Tuberous Sclerosis with Rapamycin Nanomicelles Based on Abdominal Ultrasound. Journal of nanoscience and nanotechnology. vol 21. issue 2. 2021-06-09. PMID:33183431. |
in recent years, mtor signaling pathway has been found to be the main bridge between tsc1/tsc2 gene mutation and tuberous sclerosis phenotype. |
2021-06-09 |
2023-08-13 |
Not clear |
| Xiaojun Xiao, Yayuan Zhang, Yujuan Zhang, Lijuan Wang, Hui Lu. Study on the Treatment of Tuberous Sclerosis with Rapamycin Nanomicelles Based on Abdominal Ultrasound. Journal of nanoscience and nanotechnology. vol 21. issue 2. 2021-06-09. PMID:33183431. |
although mtor inhibitors have been reported to treat tuberous sclerosis in foreign countries, there is still a lack of long-term follow-up results and clinical treatment experience in children. |
2021-06-09 |
2023-08-13 |
Not clear |
| Kyoichi Tomoto, Ayataka Fujimoto, Chikanori Inenaga, Tohru Okanishi, Shin Imai, Masaaki Ogai, Akiko Fukunaga, Hidenori Nakamura, Keishiro Sato, Akira Obana, Takayuki Masui, Yoshifumi Arai, Hideo Enok. Experience using mTOR inhibitors for subependymal giant cell astrocytoma in tuberous sclerosis complex at a single facility. BMC neurology. vol 21. issue 1. 2021-06-08. PMID:33784976. |
experience using mtor inhibitors for subependymal giant cell astrocytoma in tuberous sclerosis complex at a single facility. |
2021-06-08 |
2023-08-13 |
Not clear |
| Mouna Triki, Gianmarco Rinaldi, Melanie Planque, Dorien Broekaert, Alina M Winkelkotte, Carina R Maier, Sudha Janaki Raman, Anke Vandekeere, Joke Van Elsen, Martin F Orth, Thomas G P Grünewald, Almut Schulze, Sarah-Maria Fend. mTOR Signaling and SREBP Activity Increase FADS2 Expression and Can Activate Sapienate Biosynthesis. Cell reports. vol 31. issue 12. 2021-04-28. PMID:32579932. |
accordingly, activating mtor signaling by deleting tuberous sclerosis complex 2 (tsc2) or overexpression of srebp-1/2 is sufficient to increase fads2 mrna expression and sapienate metabolism in mouse embryonic fibroblasts (mefs) and u87 glioblastoma cells, respectively. |
2021-04-28 |
2023-08-13 |
mouse |
| Sam Amin, Andrew A Mallick, Hannah Edwards, Mario Cortina-Borja, Matthew Laugharne, Marcus Likeman, Finbar J K O'Callagha. The metformin in tuberous sclerosis (MiTS) study: A randomised double-blind placebo-controlled trial. EClinicalMedicine. vol 32. 2021-03-17. PMID:33681737. |
tuberous sclerosis complex (tsc) is a genetic disorder characterised by the development of benign tumours secondary to loss of inhibitory regulation of the mtor (mechanistic target of rapamycin) intracellular growth pathway. |
2021-03-17 |
2023-08-13 |
Not clear |
| Danielle R Weidman, Sunitha Palasamudram, Maria Zak, Robyn Whitney, Blathnaid McCoy, Eric Bouffet, Michael Taylor, Manohar Shroff, Ute Bartel. The effect of mTOR inhibition on obstructive hydrocephalus in patients with tuberous sclerosis complex (TSC) related subependymal giant cell astrocytoma (SEGA). Journal of neuro-oncology. vol 147. issue 3. 2021-03-15. PMID:32285309. |
the effect of mtor inhibition on obstructive hydrocephalus in patients with tuberous sclerosis complex (tsc) related subependymal giant cell astrocytoma (sega). |
2021-03-15 |
2023-08-13 |
Not clear |
| Philip H Iffland, Allan E Barnes, Marianna Baybis, Peter B Crin. Dynamic analysis of 4E-BP1 phosphorylation in neurons with Tsc2 or Depdc5 knockout. Experimental neurology. vol 334. 2021-03-10. PMID:32781001. |
tsc1 or tsc2 mutations cause tuberous sclerosis complex (tsc), and lead to mechanistic target of rapamycin (mtor) hyperactivation evidenced by hyperphosphorylation of ribosomal s6 protein and 4-elongation factor binding protein 1 (4e-bp1). |
2021-03-10 |
2023-08-13 |
Not clear |
| Hannah E Goldstein, Jason S Hauptma. The Putative Role of mTOR Inhibitors in Non-tuberous Sclerosis Complex-Related Epilepsy. Frontiers in neurology. vol 12. 2021-03-03. PMID:33643212. |
mtor, a ubiquitous 289 kda serine/threonine kinase in the phosphatidylinositol 3-kinase (pi3k)-related kinases (pikk) family, is dysregulated in a number of human diseases, including tuberous sclerosis complex (tsc) and epilepsy. |
2021-03-03 |
2023-08-13 |
human |
| Bo Zhang, Dongjun Guo, Lirong Han, Nicholas Rensing, Akiko Satoh, Michael Won. Hypothalamic orexin and mechanistic target of rapamycin activation mediate sleep dysfunction in a mouse model of tuberous sclerosis complex. Neurobiology of disease. vol 134. 2021-01-13. PMID:31605778. |
tuberous sclerosis complex (tsc) is a genetic disease related to hyperactivation of the mechanistic target of rapamycin (mtor) pathway and manifested by neurological symptoms, such as epilepsy and sleep disorders. |
2021-01-13 |
2023-08-13 |
mouse |
| Romina Moavero, Angelika Mühlebner, Mark Jasper Luinenburg, Dana Craiu, Eleonora Aronica, Paolo Curatol. Genetic pathogenesis of the epileptogenic lesions in Tuberous Sclerosis Complex: Therapeutic targeting of the mTOR pathway. Epilepsy & behavior : E&B. 2021-01-12. PMID:33431351. |
genetic pathogenesis of the epileptogenic lesions in tuberous sclerosis complex: therapeutic targeting of the mtor pathway. |
2021-01-12 |
2023-08-13 |
Not clear |
| Chiara Borsari, Erhan Keles, Denise Rageot, Andrea Treyer, Thomas Bohnacker, Lukas Bissegger, Martina De Pascale, Anna Melone, Rohitha Sriramaratnam, Florent Beaufils, Matthias Hamburger, Paul Hebeisen, Wolfgang Löscher, Doriano Fabbro, Petra Hillmann, Matthias P Wyman. 4-(Difluoromethyl)-5-(4-((3 Journal of medicinal chemistry. vol 63. issue 22. 2020-12-31. PMID:33166139. |
rapalogs and mtor kinase inhibitors (torki) have recently been applied to alleviate epileptic seizures in tuberous sclerosis complex (tsc). |
2020-12-31 |
2023-08-13 |
Not clear |
| Angela Peron, Francesca La Briola, Fabio Bruschi, Silvia Terraneo, Chiara Vannicola, Roberto Previtali, Sabrina Perazzoli, Emanuela Morenghi, Gaetano Bulfamante, Aglaia Vignoli, Maria Paola Canevin. Tuberous sclerosis complex (TSC), lymphangioleiomyomatosis, and COVID-19: The experience of a TSC clinic in Italy. American journal of medical genetics. Part A. vol 182. issue 11. 2020-11-27. PMID:32804431. |
this study aims at evaluating the presence and outcome of covid-19 in a cohort of italian patients with tuberous sclerosis complex (tsc) and/or lymphangioleiomyomatosis (lam), and at reviewing the possible effects of mtor inhibitors on sars-cov-2 infection. |
2020-11-27 |
2023-08-13 |
Not clear |
| Hidenari Hongyo, Hiroki Higashihara, Keigo Osuga, Eiji Kashiwagi, Shinya Kosai, Keisuke Nagai, Kaishu Tanaka, Yusuke Ono, Takeshi Ujike, Motohide Uemura, Ryoichi Imamura, Norio Nonomura, Noriyuki Tomiyam. Efficacy of prophylactic selective arterial embolization for renal angiomyolipomas: identifying predictors of 50% volume reduction. CVIR endovascular. vol 3. issue 1. 2020-11-24. PMID:33219488. |
on the other hand, mammalian target of rapamycin (mtor) inhibitors have recently been used for tuberous sclerosis (tsc)-related amls, and no comparison between the effectiveness of mtor inhibitors versus prophylactic selective tae has yet been performed. |
2020-11-24 |
2023-08-13 |
Not clear |